+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cough Hypersensitivity Syndrome Treatment Market by Drug Class, Distribution Channel - Global Forecast 2025-2030- Product Image
Cough Hypersensitivity Syndrome Treatment Market by Drug Class, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Cough Hypersensitivity Syndrome Treatment Market by Drug Class, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4989772
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cough Hypersensitivity Syndrome Treatment Market grew from USD 9.21 billion in 2023 to USD 9.82 billion in 2024. It is expected to continue growing at a CAGR of 6.81%, reaching USD 14.61 billion by 2030.

Cough Hypersensitivity Syndrome (CHS) Treatment encompasses the study, development, and deployment of therapeutic interventions aimed at managing and alleviating the heightened cough reflex characteristic of this condition. As traditional treatments may not adequately address the hypersensitivity associated with CHS, there is a necessity for innovative therapies focused on desensitizing cough reflex mechanisms or leveraging novel pharmacological pathways. The application of CHS treatments spans across clinical settings, primarily targeting patients who do not respond well to standard cough treatments, with end-users being healthcare professionals, pulmonologists, and pharmaceutical companies engaged in respiratory therapy advancements. Market insights reveal that the growing prevalence of chronic cough conditions, coupled with increasing awareness of CHS, is a key growth driver. Advances in neurobiology and respiratory medicine, identification of new biomarkers, and technological innovations such as cough detection devices present lucrative opportunities for businesses keen on entering or expanding in this niche market. However, limitations include high R&D costs, stringent regulatory requirements, and the challenge of differentiating CHS from other similar disorders, which can hinder market entry and growth. Despite these challenges, areas ripe for innovation include the development of targeted gene therapies, personalized medicine approaches using genomic insights, and integrative treatment protocols combining pharmacological and non-pharmacological interventions. The market is dynamic, driven by evolving consumer and professional understanding of cough disorders, rapid technological advancements, and the increasing demand for effective, patient-centered treatment solutions. To capitalize on market opportunities, companies should focus on collaborative research endeavors, adopt agile development methodologies to accelerate clinical trials, and ensure compliance with global regulatory standards while advocating for more streamlined approval processes. Emphasizing patient education and engagement through digital health platforms could also enhance market penetration and adoption of CHS treatments.

Understanding Market Dynamics in the Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • High prevalence of chronic lung infections diseases
    • Surge in the number of smokers globally
    • Emergence in vulnerable indoor as well as outdoor allergens
  • Market Restraints
    • Drug abuse and dependence on cough hypersensitivity syndrome drugs
  • Market Opportunities
    • Surge in research and development activities in the treatment of cough hypersensitivity syndrome
    • Government initiatives for advanced healthcare infrastructures
  • Market Challenges
    • Limited efficacy and undesirable side effects of antitussives

Exploring Porter’s Five Forces for the Cough Hypersensitivity Syndrome Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Cough Hypersensitivity Syndrome Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cough Hypersensitivity Syndrome Treatment Market

External macro-environmental factors deeply influence the performance of the Cough Hypersensitivity Syndrome Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cough Hypersensitivity Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Alvizia Healthcare Private Limited, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, Farlex Pharmaceuticals Private Limited, GlaxoSmithKline PLC, Johnson & Johnson Consumer Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Solace Biotech Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals, Inc., and WEEFSEL PHARMA.

Market Segmentation & Coverage

This research report categorizes the Cough Hypersensitivity Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Anticholinergics
    • Antihistamines
    • Antitussive Agents
    • Inhales Corticosteroids
    • Proton Pump Inhibitors
    • Short-Acting Beta-2 Agonists
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of chronic lung infections diseases
5.1.1.2. Surge in the number of smokers globally
5.1.1.3. Emergence in vulnerable indoor as well as outdoor allergens
5.1.2. Restraints
5.1.2.1. Drug abuse and dependence on cough hypersensitivity syndrome drugs
5.1.3. Opportunities
5.1.3.1. Surge in research and development activities in the treatment of cough hypersensitivity syndrome
5.1.3.2. Government initiatives for advanced healthcare infrastructures
5.1.4. Challenges
5.1.4.1. Limited efficacy and undesirable side effects of antitussives
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cough Hypersensitivity Syndrome Treatment Market, by Drug Class
6.1. Introduction
6.2. Anticholinergics
6.3. Antihistamines
6.4. Antitussive Agents
6.5. Inhales Corticosteroids
6.6. Proton Pump Inhibitors
6.7. Short-Acting Beta-2 Agonists
7. Cough Hypersensitivity Syndrome Treatment Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies
8. Americas Cough Hypersensitivity Syndrome Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cough Hypersensitivity Syndrome Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTITUSSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALES CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 105. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cough Hypersensitivity Syndrome Treatment Market, which are profiled in this report, include:
  • Alvizia Healthcare Private Limited
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Farlex Pharmaceuticals Private Limited
  • GlaxoSmithKline PLC
  • Johnson & Johnson Consumer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Solace Biotech Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals, Inc.
  • WEEFSEL PHARMA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.61 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Cough Hypersensitivity Syndrome Global Market Report 2024 - Product Image

Cough Hypersensitivity Syndrome Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Cough in Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Cough in Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 145 Pages
  • Global
From
Chronic Refractory Cough Market by Drug Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Chronic Refractory Cough Market by Drug Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Cough Suppressant Drugs Market by Disease Type, Drug Type, Age Group, Dosage Form, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cough Suppressant Drugs Market by Disease Type, Drug Type, Age Group, Dosage Form, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From

About the Cough Hypersensitivity Syndrome Drug Market

The Cough Hypersensitivity Syndrome Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat chronic cough, a condition characterized by an excessive and persistent cough. These drugs are typically used to reduce the frequency and intensity of coughing, as well as to reduce the associated symptoms of chest pain, throat irritation, and difficulty breathing. Commonly used drugs in this market include anticholinergics, beta-agonists, and leukotriene receptor antagonists. The Cough Hypersensitivity Syndrome Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in this market include GlaxoSmithKline, Merck & Co., AstraZeneca, Pfizer, Novartis, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.